Overview

• Fifty-one Republican senators led by Lindsey Graham urged HHS and the FDA to reevaluate the new generic mifepristone, suspend generic approvals, reinstate in‑person dispensing, restrict mail-order distribution, and withdraw pharmacy guidance.
• The FDA quietly approved a second generic mifepristone from Evita Solutions late last month, with officials emphasizing that generic approvals are constrained by statute and do not constitute an endorsement.
• Louisiana filed a federal suit in the Western District of Louisiana seeking to restore pre‑2023 REMS, bar mail-order dispensing, and invoke the Comstock Act, citing state abortion laws and alleging hundreds of mail-order abortions monthly in 2024.
• HHS and FDA officials say a safety review of mifepristone is underway, with the White House noting the law tightly limits the agency’s discretion when a generic drug demonstrates required equivalence.
• Anti-abortion advocates amplified accounts of alleged coercive use of abortion drugs and highlighted interstate enforcement clashes, as GOP lawmakers and groups pressed for swift reinstatement of in‑person requirements.